NCT02142049 - Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions

Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma Refractory

Interventions

DRUG

Ibrutinib

DRUG

DA-EPOCH-R

Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim

DRUG

Lenalidomide

Trial Locations (10)

SITE-9, Stony Brook

SITE-6, Bethesda

SITE-5, Baltimore

SITE-7, Charleston

SITE-4, Ann Arbor

SITE-3, Chicago

SITE-8, Albuquerque

SITE-2, Los Angeles

SITE-1, Duarte

SITE-10, Orange